Life Science News

Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain

- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies

- Initiative supports Abbott and LISC's commitment to increase diversity in healthcare and generate jobs and strengthen economies in underinvested communities

Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with the tailored growth capital, loans and support they need to compete, grow and create jobs. The initiative will support greater diversity in the healthcare industry by advancing a more inclusive supply chain for Abbott and other healthcare companies, while contributing to broader economic and health equity.

In the healthcare supply chain, the small businesses that help produce diagnostics, nutrition products, medical devices and other health technologies do not reflect the diversity of the communities they serve – which reflects a broader diversity gap in businesses across America. According to the U.S. Census Bureau , only 19% of U.S. businesses are owned by people of color and 21% are owned by women, despite representing 40% and more than half the population, respectively. Owners of diverse small businesses – including people of color and women – can help drive change, but many face challenges, with 50% unable to access loans to grow their business.

The Abbott-LISC Initiative to Support Diverse Businesses in Health aims to break down barriers that prevent diverse small businesses from providing manufacturing and essential products in healthcare. By providing targeted support, Abbott and LISC are working to build a stronger, more diverse healthcare supply chain, as well as healthier local economies and communities.

"We're committed to tearing down the barriers that diverse small-business owners often face, and to building a more inclusive supply chain in healthcare," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our new initiative with LISC takes real, pragmatic steps to make that happen."

"This partnership is a shared investment in the future of our communities and the strength of our supply chains," said LISC CEO Lisa L. Glover . "We're proud to partner with Abbott to deliver capital and technical services that enhance the infrastructure for small business growth, so owners from diverse backgrounds are better able to compete for contracts, hire more staff, and fuel economic opportunity in the communities where they operate."

Targeted Support for Diverse Small Businesses
Abbott is contributing $25 million for the initiative, including $12.5 million in loan capital and $12.5 million in grants to LISC to provide investment funding and targeted support. LISC is matching the investment with an additional $12.5 million in loan capital. This funding will support diverse small businesses in three ways:

  1. Growth capital: With Abbott grant support, LISC will provide interest-free capital to help businesses overcome hurdles to expansion, such as investing in management systems to comply with regulatory and environmental requirements. Businesses will repay LISC if and when they meet certain growth targets.
  2. Business loans: Abbott and LISC funding will provide flexible, affordable loans with terms that would not typically be available through conventional lenders.
  3. Technical assistance: An Abbott grant will support LISC in providing customized support to businesses accessing capital and loans through the initiative, including help with fulfilling investment and loan requirements and identifying and addressing specific business barriers to growth.

Eligible small businesses are those that are majority owned by people of color (including Black, Latino, Asian and Native American business owners), women, veterans, people with disabilities, people who identify as LGBTQ and other historically underrepresented groups in the U.S. with more than two years in operation and an ability to deploy capital toward business improvements and growth. To qualify, businesses should focus on manufacturing and essential business-to-business products that support the production of diagnostics, nutrition products, medical devices and other health technologies.

Collaboration Part of Broader Work to Advance Diversity, Equity, Opportunity
This joint initiative supports Abbott's 2030 Sustainability Plan , which aims to advance health access and equity through partnership and build a diverse, resilient and responsible supply chain – with specific targets to increase overall spending with diverse and small businesses 50% by 2030 and with Black- and women-owned businesses 150% by 2025. This work complements Abbott's ongoing commitment to address broader health equity challenges, including increasing diversity in clinical trials , creating opportunities in STEM for women and underrepresented groups, and empowering communities to break down social and economic barriers to better health.

The work also supports LISC's Project 10X , which bridges racial health, wealth and opportunity gaps throughout the country. The initiative helps break down historical and systemic barriers by investing in businesses, community organizations, developers and projects that are driven by and for communities of color.

To learn more about this initiative, funding eligibility and opportunities, see Abbott's site and LISC's site .

About LISC
LISC is one of the country's largest community development organizations, helping forge vibrant, resilient communities across America. We work with residents and partners to close systemic gaps in health, wealth and opportunity and advance racial equity so that people and places can thrive. Since our founding in 1979, LISC has invested $24 billion to create more than 436,320 affordable homes and apartments and develop 74.4 million square feet of retail, community and educational space.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

Cision View original content: https://www.prnewswire.com/news-releases/abbott-and-lisc-team-up-to-address-diversity-and-equity-gaps-in-the-healthcare-industry-supply-chain-301513452.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 “long haulers,” who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

Keep reading...Show less
abt stock

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

  • Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™
  • Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia

Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites Exchange (CSE:AVBT) through the previously announced merger completion with Fogchain Corp. Avisa has developed the Avisa BreathTest™ (ABT), an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in Post-COVID-19 "long haulers," who can develop acute respiratory disease, and ventilator-associated pneumonia (VAP), an indication with high morbidity and mortality.

The public listing enables Avisa to draw down over the period of three years CAD 52 million (~USD 41 million) from a share subscription and drawdown agreement put in place in 2020 with GEM GLOBAL YIELD LLC SCS (GEM), a $3.4 billion alternative investment group with offices in Paris, New York, and Los Angeles.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

Glen Eagle Resources Announces Nomination of Additional Director to the Board in Connection with Its Upcoming AGM

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. (the " Corporation ") (TSXV:GER) is pleased to announce that the Company has nominated Mr. Michel Serres for election to the Corporation's board of directors in connection with its upcoming annual general meeting (" AGM "), to be held on June 22, 2023

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Thermo Scientific Orbitrap Astral mass spectrometer combines high resolution and speed to accelerate the discovery of new proteins and advance precision medicine

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2023 Healthcare Conference on Friday, June 9, 2023 at 9:00 AM ET in New York City. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic names Ken Washington new Chief Technology and Innovation Officer

Medtronic plc (NYSE:MDT) today announced that Ken Washington Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer. In this newly created role, Dr. Washington will leverage his extensive experience leading technology development and execution across industries including robotics, consumer products, automotive, and space, to accelerate innovation-driven growth in service of the company's mission to alleviate pain, restore health and extend life. Dr. Washington will also become a member of the Medtronic Executive Committee.

"This new leadership role will help Medtronic to harness the innovative spirit of our founders and ensure we are capitalizing on our scientific and technological knowledge to invent, innovate and disrupt the healthcare technology market of the future," said Geoff Martha, chairman and CEO, Medtronic. "Dr. Washington will help Medtronic expand use of our technology platforms across our portfolio – including robotics, sensors, implantables and AI – improving our returns on investments in innovation and expanding our technological competitive advantage to drive durable growth."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease

Cover Your Bases Campaign Kicks Off Oral Health Month with ARESTIN (minocycline HCI) Patient Ambassador Alex Rodriguez

Bausch Health Companies Inc. (NYSETSX: BHC) and its oral health care business, OraPharma, today announced its collaboration with World Series Champion, Alex Rodriguez to launch a national awareness campaign about the prevalence and impact of gum disease. The Cover Your Bases campaign includes educational content about the disease and encourages patients to talk to their dentist about comprehensive treatment options. The campaign launch is timed to Oral Health Month recognized throughout June and features Alex as a patient ambassador.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
laptop, stethoscope, smartphone, pen and eyeglasses on desk

How to Invest in Medical Devices (Updated 2023)

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.

This industry covers a wide range of health and medical instruments used in the treatment, mitigation, diagnosis and prevention of diseases and physical conditions, and it continues to develop rapidly.

Examples of medical devices include neurostimulation devices, surgical implants, ultrasound imaging devices and robotic medical technology, along with insulin pumps and insulin pens for diabetes. Just as pharmaceutical companies seek to serve unmet needs, medical device companies do the same via innovative technologies.

Keep reading...Show less

Latest Press Releases

Related News

×